IL17A and neoplasm: As demonstrated in Fig. 6C, concentration of pro‐inflammatory and pro‐angiogenic cytokines including IL‐1a, IL‐2, IL‐6, IL‐10, IL‐12, and IL‐17A, in peripheral blood of tumor bearing mice receiving anti‐MUC1 nanobody was significantly lower compared to the PBS receiving group.